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Available online 3 December 2016Neuropeptides and their receptors play a role in physiological responses such as appetite, stress and inﬂamma-
tory pain. With neuropeptides having such diverse and important physiological roles, knocking-out the genes
encoding them, their receptors, parts of their regulatory sequences, or reproducing disease associated polymor-
phic variants are important steps in studying neuropeptides and how theymay contribute to disease. Previously,
knock-outs were generated usingmethods such as targeted homologous recombination in embryonic stem cells
but this method is costly and time-consuming. The CRISPR/Cas9 system has rapidly taken over the genome
editing ﬁeld and will advance our understanding of neuropeptide genes and their regulation. With CRISPR/
Cas9 technology, the time and costs involved in producing transgenic animal models, is greatly reduced. In this
review, we describe how the system can be used to manipulate genomic sequences by “knock-out” or “knock-
in” mutations in cell lines or in animal models. We also discuss the speciﬁcity of the system and methods to
limit off-target effects.When combinedwith the availability of genome sequences, CRISPR/Cas9 directed genome
editing in vitro and in vivo, promises to provide a deeper understanding of the biology of the neuropeptides in
health and disease than has ever been available before.
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Neuropeptides play a critical role in modulating a number of physi-
ologies, including inﬂammation, appetite, mood and the reward system
(Pinter et al., 2013; Lang et al., 2015; Picciotto et al., 2009) that are im-
portant in maintaining the homeostatic mechanisms required for
health. However, because few, if any, disease associated polymorphic. This is an open access article undervariants have been found in the coding regions of neuropeptide genes
using complex genome wide association studies (GWAS), interest in
the biology of neuropeptides in diseases such as obesity, depression,
chronic inﬂammatory pain and addiction has waned over the past
10 years. Critically, one important aspect of the biology of neuropep-
tides has not beenwidely explored; namely themechanisms thatmain-
tain the correct cell speciﬁc and inducible expression of the genes that
encode neuropeptides. Understanding these genomic mechanisms,
and how theymay be inﬂuenced by polymorphic variation or epigenet-
ically modulated DNA-methylation, will be the key to understandingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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derstanding of neuropeptide biology and the regulation of neuropep-
tides has been prevented in the past by an inability to easily
manipulate the coding regions or regulatory sequences involved in con-
trolling their function and expression. For example, traditional gene
targeting approaches using positive-negative selection in embryonic
stem cells proved to be too expensive, time consuming (Skarnes,
2015) and wasteful of animals to warrant its use in the deletion of
gene regulatory elements. Thus, most of the biology of these elements,
their roles in cell speciﬁc regulation of neuropeptides or the effects of
polymorphic variation on their activity remains unknown. Thankfully,
this situation has recently changed with the advent of genome editing
technologies, the foremost of which is the CRISPR/Cas9 system.
It is fair to say that, thanks to its speed, cost and its hugely reduced
animal use, the CRISPR/Cas9 system is on target for revolutionising biol-
ogy. CRISPR technology has overtaken other programmable nucleases
such as zinc ﬁnger nucleases and TALE proteins in terms of efﬁciency
and speciﬁcity and has rendered traditional embryonic stem cell (ES)
gene targeting largely obsolete. The CRISPR/Cas9 system is a program-
mable means of inducing a targeted double strand cut in genomic
DNA. CRISPR/Cas9 was derived from the natural bacterial adaptive im-
mune system that utilizes three types of CRISPR mechanisms observed
in microorganisms (Hsu et al., 2014). From the point of view of genome
editing in mammals the type two system is the most useful and was
used in the ﬁrst experiments very recently in 2013, using Cas9 for ge-
nome engineering in cells (Cong et al., 2013; Mali et al., 2013a).1.1. The discovery and development of the CRISPR/Cas9 system for genome
editing in eukaryotes
The genome of the adaptive bacterial immune system consists of
CRISPR (clustered regularly interspaced short palindromic repeats) ar-
rays that consist of direct repeat DNA sequences (Wiedenheft et al.,
2012), interspaced with ‘spacer’ sequences that are present in known
invading viruses (Sorek et al., 2008; Bolotin et al., 2005). These spacer
sequences are acquired during infection by the virus and act as a prim-
itive memory that allows the bacterium to ﬁght the virus in future. The
direct repeat sequences allow the cell to distinguish between self and
non-self (Hsu et al., 2014). CRISPR based immunity is acquired through
the integration of spacer segments of foreignDNA into the CRISPR locus.
The CRISPR locus can then process the foreign DNA into CRISPR RNA
(crRNA).
Transcribed crRNAcontains the unique crRNA sequence and an adja-
cent palindromic repeat sequence, recognisable by a trans-activating
CRISPR RNA (tracrRNA) which stimulates the processing of the RNA
byRNase III (Deltcheva et al., 2011). Annealing of processed crRNA tran-
scripts with tracrRNA allows for association with the Cas nuclease. The
crRNA and tracrRNA complex guide the Cas9 enzyme to the target se-
quence, where it will create a double strand break in the DNA (Jinek
et al., 2012).
The target DNAmust contain a protospacer adjacentmotif (PAM) se-
quence at the 3′ end of the target sequence (Jinek et al., 2012), which is
speciﬁc to the Cas9 species beingused (5′-NGG-3′ PAMsequence for the
Streptococcus pyogenes Cas9 enzyme). This is the most common type
two CRISPR system, and utilizes a 20 nucleotide crRNA thatmust imme-
diately precede a 3 nucleotide (NGG) PAM sequence (Chylinski et al.,
2013). Both the PAM and tracrRNA sequences remain constant, and
are directed to a deﬁned locus by the 20 nucleotide crRNA sequence. Be-
cause of this, it is possible to fuse the crRNA and tracrRNA sequences
into a chimeric single-guide RNA (sgRNA or gRNA) (Mali et al., 2013b;
Ma et al., 2014). Addition of the site speciﬁc 20 nucleotide crRNA se-
quence into this guide RNA is sufﬁcient to direct Cas9, provided that
the crRNA sequence is directly upstream of the NGG PAM sequence.
The development of the single-guide RNA provides an easy-to-use sys-
tem for relatively quick genome editing.The development of the CRISPR/Cas9 system for mammalian ge-
nome editing has been rapid, with the establishment of online plasmid
depositories such as Addgene (http://www.addgene.org/) and online
guide RNA design tools such as http://crispr.mit.edu/. Bioinformatics
tools (Heigwer et al., 2014) allow for quick and easy targeting and ex-
periment design. In order to engineer eukaryotic genomes a minimum
of two main components are required:
1. A guide RNA composed of a scaffold sequence (tracrRNA) binding to
the Cas nuclease, and a targeting sequence (crRNA) which mediates
binding to the intended DNA target. The tracrRNA and the crRNA are
often combined to form a single guide RNA (sgRNA). The targeting
sequence within the crRNA or sgRNA can be freely chosen with
only minor limitations; the target DNAmust be ﬂanked by a PAM se-
quence at the 3′ end (Jinek et al., 2012), and the complement of the
PAM sequence should not be present on the guide RNA.
2. The Cas9 protein, mRNA or a plasmid encoding the protein. Plasmid
expression constructs have been designed (e.g. pX330; Addgene
#42230) that only require insertion of 20 nucleotide crRNA sequence
required for directing the Cas9 complex to a deﬁned locus. In this
case, the sgRNA is expressed from the U6 polymerase III promoter,
and requires the crRNA to start with a G; the only constraint to
targeting speciﬁcity with this system is the GN20GG motif
(G + crRNA + NGG PAM). The gene encoding the Cas9 protein has
undergone a number of alterations, including the removal of one or
both of its DNA cutting domains, and the addition of a nuclear
localisation signal to guide the Cas9-gRNA complex to the nucleus.
It is important to note, however, that the CRISPR systemonly permits
directed cutting of the target genome and plays no further role in its
subsequent repair. This aspect is governed by the host cells natural
repair mechanisms. The next section of this review will explore the
cellular pathways that repair CRISPR mediated genomic breaks and
how they can be manipulated to produce the desired outcome.
1.2. Repair of CRISPR induced insertions/deletions by cellular repair
mechanisms
Following a double strand break, the cells natural repair system will
attempt to ﬁx the break. There are two types of system used by mam-
malian cells, the ﬁrst is the rapid and efﬁcient non-homologous end
joining (NHEJ) system (Valerie and Povirk, 2003). However, non-ho-
mologous end joining is error prone and has been known to introduce
unwanted sequences that compromise attempts to introduce subtle ge-
nomic changes, such as introduction of disease associated allelic vari-
ants or the targeted introduction of larger sequences, such as reporter
genes or antibody epitopes. In contrast, homology directed repair
(HDR) is more accurate than NHEJ but is less efﬁcient in the presence
of double strand cuts.
Off target activity can be reduced by up to 1500 fold by introducing
paired single strand “nicks” as opposed to double stranded cuts. This is
achieved using amutant version of the Cas9 enzyme (Cas9n) also called
D10A mutant nickase (Ran et al., 2013). If nickases are introduced with
DNA constructs called “repair templates” then the HDR pathway can in-
sert sequences within the repair template by homologous recombina-
tion thus providing a method to introduce or “knock-in” novel
sequences into the genome. The use of the “nickase” is also thought to
reduce possible off-target effects whereby the Cas9 cuts sequences else-
where in the genome that only differ from the target sequence by one or
two base pairs. Using a combination of nickases and repair templates,
targeted insertions, previously known as “knock-ins” when performed
using ES-cell targeting, can be achieved.
2. Use of CRISPR/Cas9 technology for genome editing in trans-
formed/immortalised cell culture
One of the most widespread uses of the CRISPR/Cas9 system in eu-
karyotes has been its use in transformed cell lines (Chu et al., 2015).
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many of them take on morphological features characteristic of
neurones. These cell types include SH-SY5Y neuroblastoma cells
that, in the presence of morphogens such as retinoic acid, produce
structures that resemble axons/dendrites and express many neurone
speciﬁc proteins (Korecka et al., 2013). Editing the genomes of these
cells involves the transfection of Cas9-sgRNA expression plasmids
(like pX330) that express both the guide RNA and the corresponding
Cas9 nuclease.
Homology-directed repair has a low efﬁciency in mammalian cells
and non-homology directed repair is predominant (He et al., 2016).
NHEJ directed integrations occur at a 1000 times greater frequency
than HDR (Vasquez et al., 2001). In fact, recent research has shown
that targeted knock-in is more efﬁcient in mammalian cells through
the NHEJ process compared to the HDR process (He et al., 2016). The
study also suggests that precise ligations following NHEJ repair can be
produced through the conventional NHEJ mechanism.
Homology-directed repair may be enhanced through inactivating
molecules in the non-homologous end-joining repair pathway to in-
crease the likelihood of the homology-directed repair pathway being
initiated (Chu et al., 2015). However, the method used to enhance
HDR should be carefully considered depending on the context of the ex-
periment, as the NHEJ pathway is important for repairing DNA damage
in cells. The efﬁciency of HDR is dependent on the targeted gene locus.
36% gene targeting efﬁciency was observed at the AAVS1 locus in
HEK293 cells when non homologous end joining was suppressed (Chu
et al., 2015). In contrast, the homologous recombination efﬁciency at
the TERT locus in HEK293 cells (chromosome 5p15. 33) was much
lower (b1%) (Xi et al., 2015). At least two guide RNA sequences were
used in both of these reports with varying efﬁcacy. This supports similar
observations that both the target site, and the guide RNA sequence used
to target it have drastic effects on targeting efﬁciency (Doench et al.,
2014).
Illegitimate recombination via non-homologous end joining (NHEJ)
ismore efﬁcient thanHDR at repairing double strand breaks inmamma-
lian cells (Lieber, 2010). The introduction of targeted double strand
breaks at a locus surrounded by homology from a repair template can
induceHDR by up to 100 fold, but an increase in illegitimate recombina-
tion by up to 1000 fold occurs in tandem (Sargent et al., 1997). Even
with selection strategies speciﬁc for HDR events in somatic cells, with-
out double strand break induction, the ratio of homologous/illegitimate
recombination frequencies can be as low as 1:4000 (Adair et al., 1989).
Increased frequencies of homologous recombination in stem cell
lines (Tichy et al., 2010) is a result of elevated proteins known to be in-
volved in homologous recombination (Matsunami et al., 2008). Stem
cells show decreased expression of DNA ligase IV, which is a rate limit-
ing factor for NHEJ (Riballo et al., 2009) in the majority of mammalian
cells.
Suppression of DNA ligase IV in mammalian cells has been achieved
with siRNA knockdown, a small-molecule inhibitor (SCR7) and adeno-
viral proteins (E1B55K and E4orf6) that mediate its degradation (Chu
et al., 2015). Chu et al. (2015) demonstrate that NHEJ suppression in
HEK293 cells can increase HDR efﬁciency by ﬁve to seven fold (5%with-
out NHEJ suppression to 36% with it). However, these efﬁciencies were
reported at the permissive (AAVS1) locus using a ‘trafﬁc light reporter’
assay described by (Certo et al., 2011). Similar experiments using the
same reporter system in HEK293 cells with siRNA knockdown achieved
HDR efﬁciencies of 4%, with NHEJ efﬁciency remaining high (25–30%)
(Certo et al., 2011). The authors attribute such variability to differences
in targeting and screening strategies to score genome manipulation
events. With this in mind, neither article provided selection pressure
to augment these rates. Chu et al. (2015) did note a 100% efﬁciency of
targeting a puromycinmarker intomurine stem cells via HDR and selec-
tion. AugmentedHDR at endogenous lociwithNHEJ suppression in por-
cine somatic cells (fetalﬁbroblasts) can reach efﬁciencies of 44% (Park et
al., 2016).NHEJ can also be suppressed using reversible inhibitors of cell cycle
progression to temporarily lock cellswithin the G2/Mphase (Yang et al.,
2016). This method shows no detrimental effects or toxicity in human
stem cells, and increases CRISPR mediated HDR efﬁciency by up to 6
fold. Additional chemical inhibition of NHEJ via SCR7 showed no further
increase in HDR efﬁciencies. This indicates that cell cycle arrest and
NHEJ inhibition share similar mechanisms. Zero toxicity was also ob-
servedwhen restrictingHEK293 cells to the late G2 phasewith a revers-
ible chemical inhibitor (Nocodazole), which improved CRISPRmediated
HDR efﬁciency by 11% (Lin et al., 2014). Both of these reports note a
preference for this method over chemical inhibition of NHEJ for in-
creased reliability, reduced cost and ease of implementation.
The asymmetric manner in which Cas9 binds to, and cleaves DNA
can also be used to increase HDR efﬁciency. Dissociation of Cas9 from
cleaved DNA primarily exposes the non-target 3′ strand (Richardson
et al., 2016). Single stranded oligodeoxynucleotides with homology to
this exposed region show increased HDR efﬁciencies by up to 60% in
HEK293 cells. The efﬁciency of homology-directed repair can be en-
hanced by optimising the design of single-stranded DNA donors to tar-
get the 3′ strand which is released ﬁrst.
3. Producing knock-out mutations in mice using CRISPR/Cas9
Although useful for understanding the biology of neuropeptides in a
single cell context the use of CRISPR technology in transformed cells has
limiteduse in understanding the regulatory systems that control the cell
speciﬁc and inducible expression of neuropeptide genes in vivo. In the
presence of one guide RNA, the CRISPR/Cas9 system can be used to in-
duce mutations via insertion or deletion of genetic information follow-
ing NHEJ mediated repair at the Cas9 cleavage site. Such mutations at
speciﬁc genes or gene regulatory regions will disrupt expression (Fig.
1). The precision of this method is limited by the unpredictability of
NHEJ mediated repair junctions.
An alternative method, which can be used to delete larger se-
quences, would be to use two single-guide RNA sequences. These
should ﬂank the sequence to be deleted. Each guide RNA would direct
the Cas9 to produce a double strand break at their target genomic se-
quence. If the two double-strand breaks occur simultaneously, the
DNA sequence that they ﬂankwill be cut-out and the natural-repair sys-
tem will join the two ends of DNA together.
Many have concerns over the potential off-target effects of these
methods as mismatches can occur between the target and the 20
base-pair guide RNA. One method to reduce off-target effects is to use
a Cas9 nickase mutant along with two off-set guide RNAs on opposite
strands of the target DNA (Ran et al., 2013). Amutation in a catalytic res-
idue in one of the two nuclease domains of Cas9 means that only one
nucleasewill cut, so a single strand cut in the template DNA is produced
instead of a double strand break. If two single strand breaks are pro-
duced on opposite but proximal strands, this will allow for a double
strand break to be produced. When compared to off-target mutations
produced by the Cas9 nuclease, it has been suggested that the double-
nicking method may reduce the risk of off-target effects (Ran et al.,
2013).
Conditional knock out mouse lines can also be developed using
CRISPR/Cas9 to introduce recombinase target sites (RTS). By using two
guide RNAs to target the ﬂanking ends of a gene and insert a set of
RTS, the genomic information in-between these RTS then becomes ex-
cisable after activation of a recombinase enzyme (Yang et al., 2013).
Using CRISPR/Cas9 to augment this process is considerably faster than
the traditional targeting methods in embryonic stem cells (Capecchi,
2005).
3.1. Addressing the problem of “off-target” effects
There has been much concern raised in the scientiﬁc community
over the speciﬁcity of the CRISPR/Cas9 system. Many have become
Fig. 1. Producing a knock-outmutation. The production ofmicewith a knock-outmutation produced through the non-homology end-joining (NHEJ) repairmechanism. One-cell embryos,
isolated from a donor mouse, are microinjected with Cas9 mRNA and single guide RNA (sgRNA) speciﬁc to the target DNA. The mechanism of the system is illustrated, with the sgRNA
binding to the target genomic DNA (blue region), guiding the Cas9 enzyme (in grey) to the region which then produces the double strand break. The double strand break is repaired
by NHEJ, which could include insertions, deletions or frameshift mutations, resulting in gene disruption. Embryos are transferred to a pseudopregnant host mouse and offspring are
genotyped to test for the presence of the knock-out mutation.
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to cutting the target site, would guide the Cas9 enzyme to other almost
homologous sites. New techniques, however, have been developed to
limit “off-target” effects, such as mutations in the Cas9 gene that pro-
duce a nicking enzyme or an enhanced speciﬁcity enzyme. 1500 fold re-
ductions in off target speciﬁcity (Ran et al., 2013) can be achieved with
paired targeting of a Cas9 nickase mutant (Cas9n) (Mali et al., 2013a).
Reduced off target speciﬁcity comes at the expense of HDR efﬁciencies,
with frequencies as low as 5% in human stem cells being demonstrated
(Rong et al., 2014).
The methods for the delivery of Cas9 have signiﬁcant effect on
targeting efﬁciency. Cas9-sgRNA ribonucleoprotein complexes can be
directly transfected intomammalian cells (Zuris et al., 2015). Thismeth-
od provides signiﬁcant improvements in DSB inductionwithminimised
toxicity compared to plasmid transfection. Zuris et al. (2015) also pro-
videmethods for recombinant production of Cas9, in vitro transcription
of sgRNA and ribonucleoprotein complex formation.
Other methods have also been developed to attempt to overcome
the problem of potential off-target effects. For example, an enhanced
speciﬁcity Streptococcus pyogenes Cas9 (eSpCas9) variant has been
shown to reduce off-target mutations (Slaymaker et al., 2015). The re-
search team neutralised the positively charged non-target strand
groove in SpCas9 by changing amino acids. The groove is thought to
play a role in stabilising the non-target strand of DNA and therefore,
by neutralising this groove its interaction with the non-target strand
would become less stable, and in turn, strong base-pairing of the
guide RNA at the target would be needed.
An alternative approach to reducing off target effects is explored in a
study by Hay et al. (2016) in this issue, who microinjected gRNA and
Cas9mRNA into the cytoplasmof one cellmouse embryos (demonstrat-
ed in Fig. 1). This method succeeded in producing a high proportion of
mice in which both copies of enhancers of the galanin gene and the
gene encoding cannabinoid receptor-1 had been deleted. Intriguingly,
on closer analysis Hay et al. (2016)were able to demonstrate a complete
lack of detectible off-target effects, in regions of the genome predicted
to act as potential off target sites, in these successfully targeted mouse
lines. They concluded that many of the off-target effect problems previ-
ously reported for the CRISPR system may have stemmed from studies
where plasmids expressing high levels of Cas9 and gRNA were
transfected into actively dividing immortalised cancer derived cell
lines. Due to high levels of Cas9 and gRNA in these cells, it was not sur-
prising that off-target effects eventually occurred. However, the gRNA
and Cas9 mRNA injected into one-cell embryos allowed sufﬁcient time
for site speciﬁc targeting but, because of rapid degradation, did not per-
sist long enough to induce off target effects. Additionally, it has been
shown that following the introduction of DNA to the pronucleus (circu-
lar plasmid DNA), a signiﬁcantly reduced developmental efﬁciency ofthe embryos was observed, compared to cytoplasmic, RNA injection
(Horii et al., 2014). Therefore, cytoplasmicmicroinjection of RNA is like-
ly to have contributed to the high survival rate and to speciﬁc targeting
in the study by Hay et al. (2016).
3.2. CRISPR interference
An alternative to producing knock-outs or mutations in the genome
is the use of the CRISPR interference (CRISPRi) method. This method
sterically represses transcription and works in the same way as the
knock-outmethod, where a sgRNA allows a Cas9 protein to target a spe-
ciﬁc sequence. However, in this system, the Cas9 protein is mutated so
that it is catalytically inactive (dCas9) and binds to the target sequence
to block transcriptional apparatus at that site (Larson et al., 2013).
Therefore, gene transcription is inhibited, and the activity of the gene
is removed without cutting or mutating the DNA sequence. This gene
knock-down can be reversed (Qi et al., 2013) as there is no change to
the DNA sequence. The level of gene repression can also be modulated
by using the CRISPRi system, by using multiple sgRNAs to target parts
of the same gene (Larson et al., 2013) or multiple sgRNAs can be used
to concurrently control several different genes,whilstmaintaining spec-
iﬁcity (Qi et al., 2013). CRISPRi is therefore a valuable tool which can be
used for and has the potential for development in several applications
including screening for gene function and for the production of induc-
ible gene expression systems (Dominguez et al., 2016).
4. Using CRISPR/Cas9 to introduce single base pair changes
The production of genetically modiﬁed animals is important for the
study of the development of disease and their treatment. Whilst tissue
or primary cell culture provide useful models for researching disease,
results from in vivomodels often differ because of the genetic and phys-
iological make-up of a complete organism (Doyle et al., 2012). Although
tissue and primary cell culture models are relevant for the study of dis-
ease, in vivo studies provide more relevance to human disease. There-
fore, the knock-in of speciﬁc DNA sequences such as, sequences
containing SNPs, conditional alleles or even human versions of genes
or cis-regulatory regions is critical for understanding disease progres-
sion and treatment. Traditionally, DNA sequences have been introduced
to mice via artiﬁcial chromosomes, viral vectors or by the pronuclear
microinjection of embryos with DNA which randomly integrates into
the genome or homologous recombination in embryonic stem cells
and more recently, the use of ZFNs (Brown et al., 2013). However, the
CRISPR/Cas9 system provides a far more efﬁcient, rapid method for
the introduction of DNA sequences in mice. By co-injecting Cas9 and a
sgRNA speciﬁc to the target sequence along with a single stranded oli-
gonucleotide template DNA strand which has homology to the target
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sertion of the DNA strand. Thismethod could be used for example, to in-
sert speciﬁc base pair mutations to enable the study of SNPs (Inui et al.,
2014; Armstrong et al., 2016) (Fig. 2).
5. Introducing larger DNA constructs and reporter constructs
Although homology-directed repair is not highly efﬁcient, the
knock-in of large DNA constructs has been achieved. Typically, a double
stranded DNA repair template is used for the integration of large con-
structs via HDR (Lee et al., 2015). An example of the knock-in of a larger
construct is shown in Fig. 3. HDR efﬁciency is rapidly lost with increas-
ing insert size, with particular reference to those over 3 kbp (Perez et al.,
2005). Interestingly, several studies (prior to CRISPR) showing high ef-
ﬁciency of HDR with inserts N1 kb (Liang et al., 1998; Brenneman et
al., 1996), direct double strand breaks to sites that are included within
a double stranded DNA repair template. Resection of these broken
ends provides immediate single stranded homology to the genomic
locus, and annealing would induce HDR via routes similar to that seen
with single stranded oligodeoxynucleotides. Single strand oligonucleo-
tide repair templates can be used for HDR of 100 bp inserts as Park et
al. (2016) have demonstrated. However, their efﬁciency at stimulating
HDR is up to 8 fold less than that of an identical double stranded plasmid
donor (Davis andMaizels, 2014). This may be a reﬂection of their limit-
ed transfection efﬁciency and stability. The use of single-stranded
oligodeoxynucleotides (ssODNs) with the CRISPR-Cas9 system has
allowed for the knock-in of GFP in rat and even the knock-in of aFig. 2. The introduction of a point mutation. A single stranded repair template is co-injected w
mutation ﬂanked by homology arms (indicated by green and orange regions of homology)
homology directed repair follows, with the insertion of the point mutation into the genomic D
how different alleles of a SNP can be studied using CRISPR.200 kb BAC containing a human gene or 6.2 kb human gene in rat zy-
gotes (Yoshimi et al., 2016). Long ssODNs can be used as the target
donor and co-injected into the embryo pronucleus with a gRNA
targeting the genomic DNA and Cas9 mRNA. For example, Yoshimi et
al. (2016) knocked in a GFP reporter Cassette into rat zygotes using an
lsODNof 837bpwith 60 bphomologous arms at either end. Alternative-
ly, two ssODNs can be co-injected with plasmid DNA, gRNAs (to target
the cut site of the genomic DNA and to target the plasmid DNA cut
site) and Cas9 mRNA. The two ssODNs will ligate the ends of the plas-
mid DNA into the genomic DNA. This method has been used by the
same group to knock-out a gene cluster and knock-in one human
gene into rats. The method allows for a more simplistic approach to
the knock-in of DNA without the need to construct homology arms.
Another group however, has successfully knocked-in 8 or 11 kb se-
quences into the genomic ‘safe harbour’ site, Rosa26, using homology
directed repair in C57BL/6 zygotes (Chu et al., 2016). Interestingly,
they also indicate that knock-in frequency could be increased when
Cas9mRNAwas combinedwith Cas9 protein andmicroinjected into zy-
gotes which were cultured to blastocysts. They suggest that the activity
of the Cas9 is more persistent as the microinjected protein would ﬁrst
initiate double strand breaks and homology-directed repair, and this
initial activity is enhanced as new Cas9 is translated from mRNA.
6. Conclusions
The advent of the CRISPR/Cas9 systemhas greatly enhanced the efﬁ-
ciency of genome editing. Its use in cells and animal models has theith the sgRNA and the Cas9 mRNA. This single stranded oligonucleotide contains a point
to elicit homology directed repair. After Cas9 produces a double strand break (DSB),
NA target region. In this example, a C to T point mutation is produced and demonstrates
Fig. 3. The introduction of a large DNA construct. Larger DNA constructs follow similar principals to single base knock-ins, except that a double stranded DNA construct is usually used as
the repair template. In this example, the double stranded repair template contains a sequence of interest that is to be inserted into the genome, which is ﬂanked by two homology regions
that correspond to the target locus. One of these homology arms should be no less than 100 bp away from the intended sgRNA cleavage site.Whilst the transgene size can vary, homology
regions are typically between 800–1400 kbp.
24 E.A. Hay et al. / Neuropeptides 64 (2017) 19–25potential for understanding neuropeptide gene function and gene regu-
lation by targeting both genes and their regulatory elements. Therefore,
the technology is likely to have a signiﬁcant role in elucidating gene reg-
ulation of neuropeptides leading to a better understanding of the phys-
iological roles and disease susceptibility associated with mis-regulation
of neuropeptides.
In this review, we have summarised different mechanisms of the
CRISPR/Cas9 system, highlighting the fact that producing a knock-out
mutation can be donemore efﬁciently than producing a knock-inmuta-
tion. The efﬁciency of knock-in may be further reduced by that fact that
the introduction of DNA to the pronucleus can be damaging, due to
physical damage from the microinjection and by possible random inte-
gration of the DNA into the genome. Another possible problemwith in-
troducing DNA to one-cell stage embryos is that DNA is known to
adhere to glass, and therefore, less DNA than expectedmay be delivered
to the cell via the glass micropipette.
We have also highlighted methods used to limit off-target effects,
such as the double nicking method and by the introduction of RNA to
one-cell stage embryos rather than DNA. Furthermore, the concept of
inducible and reversible gene knock-out by the CRISPR interference
method has been introduced. Overall, the CRISPR/Cas9 technology has
been quite extensively examined, is developing rapidly and has great
potential for exploring gene regulation of neuropeptides.Acknowledgements
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